Pneumococcal conjugate vaccine for young children

American Family Physician

Volumn 63, Issue 10, 2001, Pages

  Zimmerman, Richard Kent ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

CHILD; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HIGH RISK POPULATION; HUMAN; IMMUNIZATION; INFANT; MEDICAL SOCIETY; REVIEW; RISK FACTOR; SEROTYPE; SIDE EFFECT; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGE FACTORS; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COMORBIDITY; HUMANS; IMMUNIZATION SCHEDULE; INFANT; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PRACTICE GUIDELINES; RISK FACTORS; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; VACCINES, CONJUGATE;

EID: 0035873238     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Preventing pneumococcal disease among infants and young children: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
2. Bacterial meningitis in the United States in 1995
3. Emergence of drug-resistant pneumococcal infections in the United States
4. Streptococcus pneumoniae carriage in children attending 59 Canadian child care centers. Toronto Child Care Centre Study Group
5. Streptococcus pneumoniae
6. Epidemiologic studies of Streptococcus pneumoniae in infants: Acquisition, carriage, and infection during the first 24 months of life
7. Risk factors for invasive pneumococcal disease in children: A population-based case-control study in North America
8. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team
9. Antibody response to pneumococcal vaccination in children younger than five years of age
10. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants
11. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers
12. Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978-1994: Implications for development of a conjugate vaccine
13. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group
14. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children
15. Policy statement: Recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis